Contineum Therapeutics, Inc. announced the appointment of Sarah Boyce, President and Chief Executive Officer of Avidity Biosciences, Inc., as an independent member of its Board of Directors. Ms. Boyce brings over 25 years of global commercial and clinical development expertise in the life sciences industry to Contineum?s board. Ms. Boyce has extensive expertise in global pharmaceutical product development and commercialization, business operations, strategic planning and execution, and has a proven track record of successfully bringing over 20 products to market and scaling companies.

Currently, Ms. Boyce serves as President and Chief Executive Officer and as a member of the Board of Directors of Avidity Biosciences, Inc. Prior to joining Avidity, Ms. Boyce served as a Director and President of Akcea Therapeutics, Inc., and as Chief Business Officer at Ionis Pharmaceuticals, Inc., where she was responsible for business development, alliance management, patient advocacy and investor relations. Before Ionis, Ms. Boyce served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc., and held various positions of increasing responsibility with Alexion Pharmaceuticals Inc., Novartis Group AG, Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also previously served on the Board of Directors of Berkeley Lights Inc. and currently serves on the board of directors of OmniAb, Inc. Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England.